Jefferies Group Weighs in on DBV Technologies SA -‘s FY2021 Earnings (DBVT)

DBV Technologies SA – (NASDAQ:DBVT) – Equities researchers at Jefferies Group issued their FY2021 earnings estimates for DBV Technologies SA – in a research report issued on Wednesday. Jefferies Group analyst E. Yang expects that the firm will earn $6.08 per share for the year. Jefferies Group has a “Buy” rating and a $47.00 price target on the stock.

Several other brokerages have also recently issued reports on DBVT. Societe Generale raised shares of DBV Technologies SA – from a “hold” rating to a “buy” rating in a research note on Thursday. Leerink Swann reaffirmed an “outperform” rating on shares of DBV Technologies SA – in a research note on Wednesday. Zacks Investment Research cut shares of DBV Technologies SA – from a “buy” rating to a “hold” rating in a research note on Tuesday, January 17th. Finally, Natixis raised shares of DBV Technologies SA – from a “neutral” rating to a “buy” rating in a research note on Friday, February 17th. Six investment analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus target price of $46.50.

Your IP Address:

DBV Technologies SA – (NASDAQ:DBVT) opened at 34.88 on Friday. The company’s 50-day moving average is $35.33 and its 200 day moving average is $35.61. The firm’s market cap is $1.60 billion. DBV Technologies SA – has a 12 month low of $27.02 and a 12 month high of $37.98.

Institutional investors have recently made changes to their positions in the company. Norges Bank acquired a new position in shares of DBV Technologies SA – during the fourth quarter valued at about $1,757,000. Castleark Management LLC boosted its position in shares of DBV Technologies SA – by 136.9% in the fourth quarter. Castleark Management LLC now owns 9,690 shares of the company’s stock valued at $340,000 after buying an additional 5,600 shares in the last quarter. Perceptive Advisors LLC acquired a new position in shares of DBV Technologies SA – during the fourth quarter valued at about $21,452,000. Arrowpoint Asset Management LLC boosted its position in shares of DBV Technologies SA – by 12.6% in the fourth quarter. Arrowpoint Asset Management LLC now owns 832,990 shares of the company’s stock valued at $29,263,000 after buying an additional 93,255 shares in the last quarter. Finally, Acuta Capital Partners LLC boosted its position in shares of DBV Technologies SA – by 63.3% in the fourth quarter. Acuta Capital Partners LLC now owns 91,898 shares of the company’s stock valued at $3,228,000 after buying an additional 35,638 shares in the last quarter. 48.96% of the stock is currently owned by institutional investors.

DBV Technologies SA – Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

5 Day Chart for NASDAQ:DBVT

Receive News & Ratings for DBV Technologies SA - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA - and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply